Central Nervous System (CNS) Stimulant Drugs Market Size & Share, by Type (Amphetamines, Methylphenidate), End User (Adolescents, Adults, Hospitals) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5524
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Central Nervous System (CNS) Stimulant Drugs Market size is anticipated to reach USD 20 Billion by the end of 2036, growing at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of CNS stimulant drugs was over USD 10 Billion. The is experiencing a robust growth trajectory, primarily propelled by the escalating prevalence of attention deficit hyperactivity disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity, affecting both children and adults. The surge in ADHD cases can be attributed to a multitude of factors, including heightened awareness, improved diagnostic methods, and evolving societal expectations. As awareness campaigns and educational initiatives gain momentum, more individuals with ADHD symptoms are being identified and seeking medical intervention. According to the Centers for Disease Control and Prevention (CDC), approximately 9.4% of children aged 2-17 in the United States were diagnosed with ADHD in 2020.

This represents a notable increase from previous years, signifying the expanding CNS stimulant drugs market. The trend is not confined to the U.S. alone; similar patterns are observed globally, underlining the global nature of this growth driver. The market typically includes medications that stimulate the central nervous system, often prescribed for conditions such as attention deficit hyperactivity disorder (ADHD), narcolepsy, and sometimes depression. Commonly prescribed CNS stimulants include medications like methylphenidate and amphetamine derivatives.


Central Nervous System (CNS) Stimulant Drugs Market
Get more information on this report: Request Free Sample PDF


Central Nervous System (CNS) Stimulant Drugs Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~8%

Base Year Market Size (2023)

~ USD 10 Billion

Forecast Year Market Size (2036)

~ USD 20 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Central Nervous System (CNS) Stimulant Drugs Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Increasing Prevalence of Attention Deficit Hyperactivity Disorder (ADHD): The central nervous system (CNS) stimulant drugs market is witnessing a substantial upswing due to the rising prevalence of attention deficit hyperactivity disorder (ADHD). ADHD, a neurodevelopmental disorder affecting both children and adults, has seen a notable increase in diagnosis rates owing to heightened awareness, improved diagnostic tools, and evolving societal norms. As more individuals with ADHD symptoms are identified, the demand for CNS stimulant drugs, such as methylphenidate and amphetamine derivatives, is escalating. In the year 2020, the Centers for Disease Control and Prevention (CDC) reported that approximately 9.4% of children aged 2-17 in the United States were diagnosed with ADHD, signifying a significant patient pool.
  • Increasing Mental Health Awareness and Diagnosis Rates: The growing awareness of mental health issues and increased diagnosis rates are key drivers propelling the CNS stimulant drugs market. A global shift toward acknowledging and addressing mental health concerns has led to more individuals seeking professional help. According to the World Health Organization (WHO), the global prevalence of mental health disorders was estimated to be 10% in 2017. As mental health awareness continues to rise, there is a corresponding increase in the identification and treatment of conditions like ADHD, fueling the demand for CNS stimulant medications.
  • Expanding Geriatric Population and Cognitive Decline Concerns: The expanding geriatric population, coupled with concerns related to cognitive decline, is contributing significantly to the growth of the market. As the elderly demographic increases, so does the prevalence of age-related cognitive disorders. Each of these growth drivers signifies a distinct facet of the market expansion, ranging from evolving demographics and societal trends to technological innovations and off-label applications.

Challenges

  • Safety Concerns and Potential for Abuse: A primary challenge confronting the central nervous system (CNS) stimulant drugs market revolves around safety concerns and the potential for abuse. Stimulant medications, such as amphetamines and methylphenidate, carry a risk of misuse and dependency, particularly in non-prescribed contexts. The prevalence of stimulant abuse, especially among adolescents and young adults, raises apprehensions about the long-term safety and ethical use of these medications.
  • Regulatory Scrutiny and Prescription Restrictions
  • Generic Competition and Patent Expirations


Central Nervous System (CNS) Stimulant Drugs Segmentation

Type (Amphetamines, Methylphenidate)

The methylphenidate segment in the CNS stimulant drugs market is estimated to gain the largest revenue share of 60% in the year 2036. The global increase in mental health awareness positively influences the methylphenidate segment. As societies become more attuned to mental health issues, individuals are more likely to seek diagnosis and treatment for conditions like ADHD. This heightened awareness contributes to a larger patient pool, driving the demand for methylphenidate. The World Health Organization (WHO) reported that the global prevalence of mental health disorders was approximately 10% in 2019. The increasing acknowledgment of mental health conditions on a global scale highlights the importance of pharmaceutical interventions such as methylphenidate in addressing neurological disorders.

End User (Adolescents, Adults, Hospitals)

The hospitals segment in the central nervous system (CNS) stimulant drugs market is expected to garner a significant share in the year 2036. Technological advancements in diagnostic tools play a crucial role in the growth of the hospitals segment. Hospitals adopt state-of-the-art technologies for accurate neuroimaging, cognitive assessments, and other diagnostic procedures. Advanced diagnostic capabilities enable precise evaluations of neurological disorders, facilitating targeted treatment plans that may include CNS stimulant drugs. The use of advanced neuroimaging techniques, such as functional magnetic resonance imaging (fMRI), has increased by 25% in hospitals, according to a report by the Radiological Society of North America. These tools enhance diagnostic accuracy and guide healthcare professionals in tailoring interventions for patients with neurological conditions. The hospitals segment in the market is propelled by a combination of increasing disorder incidences, the adoption of multidisciplinary treatment approaches, and societal shifts toward mental health awareness.

Our in-depth analysis of the global central nervous system (CNS) stimulant drugs market includes the following segment

Type

  • Amphetamines
  • Methylphenidate

End User

  • Adolescents
  • Adults
  • Hospitals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Central Nervous System (CNS) Stimulant Drugs Industry - Regional Synopsis

APAC Market Forecast

The CNS stimulant drugs market in the Asia Pacific region is projected to hold the largest revenue share of 38% by the end of 2036. Technological advancements in healthcare infrastructure are playing a pivotal role in the growth of the market in the Asia Pacific region. Improved access to advanced diagnostic tools, telehealth services, and electronic health records enhances the diagnosis and management of neurological disorders, contributing to the overall market expansion. A report indicates that the Asia Pacific region has witnessed a 30% increase in the adoption of digital health technologies over the past five years. This technological progress facilitates efficient healthcare delivery, supporting the diagnosis and prescription of CNS stimulant drugs for neurological conditions. The Asia Pacific region's market is influenced by a combination of factors, including the changing prevalence of neurological disorders, lifestyle shifts, and advancements in healthcare infrastructure.

North American Market Statistics

The central nervous system (CNS) stimulant drugs market in the North America region is projected to hold the second largest share during the forecast period. The increasing prevalence of attention deficit hyperactivity disorder (ADHD) is a primary growth driver for the market in North America. ADHD is a neurodevelopmental disorder commonly diagnosed in children and adults. The growing recognition of ADHD and improved diagnostic methods contribute to a higher number of reported cases. According to the Centers for Disease Control and Prevention (CDC), in the United States, approximately 9.4% of children aged 2-17 were diagnosed with ADHD in 2020. This represents a significant increase from previous years, highlighting the substantial demand for CNS stimulant drugs to manage ADHD symptoms. The increased diagnosis of ADHD in adults is another crucial growth driver. As awareness about adult ADHD grows and mental health stigma decreases, more adults are seeking diagnosis and treatment. This expansion of the patient demographic contributes to the overall demand for central nervous system (CNS) stimulant drugs market in the region

Research Nester
Central Nervous System (CNS) Stimulant Drugs Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Central Nervous System (CNS) Stimulant Drugs Market

top-features-companies
    • Shire Pharmaceuticals LLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis International AG
    • Johnson & Johnson
    • Eli Lilly and Company
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • AbbVie Inc.
    • Purdue Pharma L.P.
    • Mallinckrodt Pharmaceuticals

In-the-news

In The News

  • Novartis acquired The Medicines Company for USD 7.6 billion, gaining Ziextenz™, a heart failure treatment with potential for expanded applications. This strengthened Novartis' cardiovascular offerings and positioned them for growth in this sector.
  • Novartis merged its generics business with Sandoz, creating a global generics leader with a strengthened market position and increased efficiency. This streamlined structure optimized resource allocation and enhanced competitiveness in the generics market.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5524
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of central nervous system (CNS) stimulant drugs is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market Shire Pharmaceuticals LLC, Novartis International AG, Johnson & Johnson, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Central Nervous System Stimulant Drugs Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying